Plasma EBV DNA clearance rate as a novel prognostic marker for metastatic/recurrent nasopharyngeal carcinoma

Clinical Cancer Research

Volumn 16, Issue 3, 2010, Pages 1016-1024

  Wang, Wen Yi ^a   Twu, Chih Wen ^b,d   Chen, Hsin Hong ^b   Jan, Jian Sheng ^b   Jiang, Rong San ^b   Chao, Jeffrey Y C ^b   Liang, Kai Li ^b   Chen, Kuan Wen ^b   Wu, Ching Te ^b   Lin, Jin Ching ^b,c,d  

^a HUNGKUANG UNIVERSITY   (Taiwan)

^b TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C; NAVELBINE; VIRUS DNA;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DISEASE MARKER; EPSTEIN BARR VIRUS; FEMALE; HALF LIFE TIME; HEAD AND NECK CANCER; HUMAN; KAPLAN MEIER METHOD; MAINTENANCE THERAPY; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NASOPHARYNX CANCER; NONHUMAN; PLASMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

DNA, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; METABOLIC CLEARANCE RATE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM METASTASIS; PROGNOSIS;

EID: 76049083072     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2796     Document Type: Article

References (20)

1. Teo PML, Kwan WH, Chan ATC, et al. How successful is high-dose (≥60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys 1998;40:897-913.
2. Chang JTC, See LC, Liao CT, et al. Locally recurrent nasopharyngeal carcinoma. Radiother Oncol 2000;54:135-42.
3. Leung TW, Tung SY, Sze WK, et al. Salvage radiation therapy for locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2000;48:1331-8.
4. Teo PML, Kwan WH, Lee WY, et al. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer 1996;77:2423-31.
5. Ong YK, Heng DM, Chung B, et al. Design of a prognostic index score for metastatic nasopharyngeal carcinoma. Eur J Cancer 2003;39:1535-41.
6. Toh CK, Heng D, Ong YK, et al. Validation of a new prognostic index score for disseminated nasopharyngeal carcinoma. Br J Cancer 2005;92:1382-7.
7. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med 2004;350:2461-70.
8. Lo YMD, Chan LYS, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-91.
9. Lo YMD, Chan ATC, Chan LYS, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res 2000;60:6878-81.
10. Chan ATC, Lo YMD, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002;94:1614-9.
11. Leung SF, Chan ATC, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer 2003;98:288-91.
12. Leung SF, Zee B, Ma BB, et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24:5414-8.
13. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer 1981;47:207-14.
14. Khanfir A, Frikha M, Ghorbel A, et al. Prognostic factors in metastatic nasopharyngeal carcinoma. Cancer Radiother 2007;11:461-4.
15. Hong RL, Sheen TS, Ko JY, et al. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. Br J Cancer 1999;80:1962-7.
16. Lin JC, Wang WY, Liang WM, et al. Long-term prognostic effects of plasma Epstein-Barr Virus DNA by minor groove binder-probe realtime quantitative PCR on nasopharyngeal carcinoma patients receiving concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007;68:1342-8.
17. Ma BBY, King A, Lo YMD, et al. Relationship between pretreatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:714-20.
18. Lo YMD, Leung SF, Chan LYS, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res 2000;60:2351-5.
19. To EWH, Chan KCA, Leung SF, et al. Rapid clearance of plasma Epstein-Barr virus DNA after surgical treatment of nasopharyngeal carcinoma. Clin Cancer Res 2003;9:3254-9.
20. Ngan RKC, Lau WH, Yip TTC, et al. Remarkable application of serum EBV EBER-1 in monitoring response of nasopharyngeal cancer patients to salvage chemotherapy. Ann N Y Acad Sci 2001;945:73-9.